Fermenta Biotech reported a 14% rise in consolidated revenue to ₹548 crore for FY26. The company recommended a final dividend of ₹3.75 per share, an increase from the previous year.

Fermenta Biotech Reports Strong FY26 Performance with 14% Revenue Growth

Fermenta Biotech's consolidated revenue reached ₹548 crore in FY26, a 14% increase over the previous year. Net profit stood at ₹70 crore.

Reader Takeaway: Core revenue growth and patent win offer future potential, while capex execution and product concentration are key watch points.

What just happened

Fermenta Biotech announced its financial results for the fiscal year ending March 2026 (FY26), reporting a consolidated revenue of ₹548 crore, marking a 14% year-on-year growth. The company also achieved a net profit of ₹70 crore and recommended a final dividend of ₹3.75 per equity share.

Why this matters

The results indicate a positive trajectory for the company, with core business growth excluding real estate contributing significantly. The proposed dividend increase reflects management confidence in the company's financial health and future prospects. Strategic moves like a new patent for plant-source Vitamin D3 and capacity expansion signal a focus on innovation and market leadership.

The backstory

Fermenta Biotech has a track record of ten consecutive quarters of positive results. In the previous fiscal year (FY25), consolidated revenue was ₹481 crore, and net profit was ₹76 crore, which included a one-off ₹45 crore from real estate income. The company has been focusing on strengthening its balance sheet and diversifying its product portfolio.

What changes now

The company has approved a ₹110 crore capital expenditure program for its Dahej facility, with a significant portion dedicated to plant-source Vitamin D3 and Calcifediol, alongside enzyme biocatalysis. The successful commissioning and operation of these expanded capacities are expected to drive future revenue and profitability.

Risks to watch

Key concerns include the execution risk associated with the new capex program, the potential impact of product concentration in Vitamin D3 despite diversification efforts, and the temporary strain on liquidity due to increased working capital for anticipated demand.

Peer comparison

While specific peer comparisons are not detailed in the filing, Fermenta Biotech's focus on Vitamin D3, plant-source alternatives, and enzyme technology places it within the specialized nutrition and biotechnology sectors.

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹548 crore (up 14% from FY25's ₹481 crore).
• Net Profit FY26: ₹70 crore (vs. ₹76 crore in FY25).
• Free Cash Flow FY26: ₹62 crore (tripled from FY25's ₹19 crore).
• Gross Debt FY26: ₹109 crore (flat from FY25).
• Final Dividend FY26: ₹3.75 per share (up from ₹2.50 in FY25).
• VITADEE Green Patent granted: September 2025.
• Dahej Capex Approval: December 2025 (₹110 crore).
• Environment Division Divestment: Effective October 1, 2025 (₹19 crore).

What to track next

Investors should monitor the progress of the Dahej capacity expansion, the ramp-up and market adoption of the VITADEE Green technology, and the company's working capital management as it scales operations.